ABG
AMLX icon

Ally Bridge Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Ally Bridge Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-437,391
Closed -$5.94M – 19
2025
Q3 		$5.94M Buy
+437,391
New +$4.12M 3.62% 10
2024
Q1 		– Sell
-275,773
Closed -$4.06M – 23
2023
Q4 		$4.06M Buy
275,773
+3,083
+1% +$47.3K 2.42% 17
2023
Q3 		$4.99M Buy
+272,690
New +$5.77M 5.86% 8

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Ally Bridge Group's AMLX Position: Q4 2025 in Review

Ally Bridge Group sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2025, closing a stake of 437,391 shares — an estimated $5.94M sold.

Ally Bridge Group first reported a position in AMLX in Q3 2023 and held it in 3 quarters. The position peaked at $5.94M in Q3 2025. 179 funds tracked by Wall St. Rank hold AMLX as of Q4 2025.

  • Ally Bridge Group reported no remaining Amylyx Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Ally Bridge Group sold 437,391 Amylyx Pharmaceuticals shares in Q4 2025, an estimated $5.94M.
  • Ally Bridge Group first reported a position in Amylyx Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Ally Bridge Group's Amylyx Pharmaceuticals position peaked at $5.94M in Q3 2025.
  • 179 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2025.

Based on Ally Bridge Group's 13F filing for Q4 2025, filed 17 Feb 2026.